Matthias Willmann

This inventor holds 4 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignee: Novartis Ag. Active years: 2013-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matthias Willmann. Retrieved from https://idiyas.com/inventor/matthias-willmann

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 4 (Patent Applications = 2)

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 1.6

ph-index = 1

Forward Citations = 4(Granted Patents)

Company Filing History:

4 out of 3,978

Novartis Ag

patents

Years Active: 2013-2023

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11612659 - Anti-CD40 antibody formulation delivery device (2023-03-28),

2. 10588976 - Anti-CD40 antibody formulation (2020-03-17),

3. 10111958 - Anti-CD40 antibody formulation (2018-10-30),

4. 8618172 - Galenical formulations of organic compounds (2013-12-31),

Title: Matthias Willmann: Innovator in Antibody Formulation

Introduction

Matthias Willmann is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of antibody formulation, holding a total of 4 patents. His work focuses on improving the delivery mechanisms of therapeutic antibodies, which are crucial in modern medicine.

Latest Patents

Willmann's latest patents include innovative formulations for Anti-CD40 antibodies. These antibodies are designed as lyophilisates or liquid formulations, allowing for high concentrations of the active ingredient. The lyophilisates can be reconstituted to create a solution with minimal antibody aggregation, ensuring effective delivery to patients. The aqueous compositions can achieve concentrations of at least 50 mg/ml and may include various components such as sugars, buffering agents, surfactants, and free amino acids.

Career Highlights

Throughout his career, Matthias Willmann has worked with prominent companies in the pharmaceutical industry, including Novartis AG and Noden Pharma DAC. His experience in these organizations has contributed to his expertise in antibody formulation and delivery systems.

Collaborations

Willmann has collaborated with various professionals in his field, including Claudia Mueller, enhancing the development of innovative solutions in antibody therapies.

Conclusion

Matthias Willmann's contributions to antibody formulation represent a significant advancement in therapeutic delivery systems. His innovative patents and collaborations continue to influence the field of medicine positively.

Profile summary based on public USPTO records.